bevacizumab + sintilimab + temozolomide

The combination of bevacizumab, sintilimab, and temozolomide is an innovative three-agent regimen used primarily for the treatment of recurrent glioblastoma. This combination therapy has shown promising antitumor activity in clinical studies. ## Description This is a three-drug combination therapy that combines: 1. Bevacizumab - A monoclonal antibody targeting vascular endothelial growth factor (VEGF) that inhibits angiogenesis 2. Sintilimab - A PD-1 inhibitor (immune checkpoint inhibitor) 3. Temozolomide (TMZ) - An alkylating chemotherapy agent The regimen typically involves sintilimab (200 mg) administered every three weeks, bevacizumab (10 mg/kg) given every three weeks, and temozolomide (200 mg/m² orally) administered for 5 days every 28 days.[1][2] In a retrospective study of eight patients with recurrent glioblastoma, this combination showed promising antitumor activity with a median progression-free survival of 3.34 months. The objective response rate was 62.5%, which is notably higher than the response rates typically seen in previous clinical studies of combination therapies for recurrent glioma.[1][2] The treatment demonstrated good tolerability with manageable adverse events. No grade 4 or 5 adverse events were reported in the retrospective analysis.[2] ## Current Development Status This combination is currently being evaluated in a Phase 2, open-label, multicenter, single-arm study designed to assess its efficacy and safety in patients with recurrent glioblastoma. The study aims to enroll approximately 30 patients.[3][4]

Brand names

Tyvyt (sintilimab)Avastin (bevacizumab)Temodar (temozolomide)